Immunohistochemical staining of Bcl-2 Oncoprotein  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

Bcl-2 Oncoprotein [100/D5] Antibody (cGMP).

$ 158.00$ 598.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD72
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Mouse IgG1

Product NumberDescriptionPrice
QIVD72-0.1ml Size: 0.1 ml, Format: Concentrate $ 128.00
QIVD72-0.5ml Size: 0.5 ml, Format: Concentrate $ 298.00
QIVD72-1ml Size: 1 ml, Format: Concentrate $ 488.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD72-0.1ml
Bcl-2 Oncoprotein General Information
Alternate Names
Molecular Weight
26.3 kDa
Chromosomal Location
q21.33 [chr: 18] [chr_start: 63123346] [chr_end: 63320128] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolBCL2
Entrez Gene ID596
RefSeq Protein Accession(s)NP_000648; NP_000624
RefSeq mRNA Accession(s)XM_011526135; NM_000633; XR_935248; XM_017025917; NM_000657
RefSeq Genomic Accession(s)NG_009361; NC_000018
UniProt ID(s)P10415
PharmGKB ID(s)PA25302
KEGG Gene ID(s)hsa:596
Associated Diseases (KEGG IDs)A chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. {ECO:0000269|PubMed:2875799, ECO:0000269|PubMed:3285301}.
General Description of Bcl-2 Oncoprotein .
The bcl-2 product is considered to act as an inhibitor of apoptosis. Bcl-2 expression is inhibited in germinal centers where apoptosis forms part of the B cell production pathway. Reactive follicles show no staining for bcl-2, whereas the cells in neoplastic follicles exhibit membrane staining. Bcl-2 alpha oncoprotein has been shown to inhibit apoptosis.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Monoclonal
Anti-Bcl-2 Oncoprotein Antibody Clone: 100/D5
Host and Isotype: Mouse IgG1
Recommended Positive Control Sample: Tonsil
Cellular Localization of Antibody 100/D5 Staining: Cell membrane
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: BALB/C mice were injected with synthetic bcl-2 peptide.
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

Bcl-2 Oncoprotein Information for Pathologists

Summary:

BCL2 is a proto-oncogene at locus 18q21.3 the plays a role in inhibiting apoptosis. The BCL2 protein has a M.W. of 25 kDa.

Common Uses By Pathologists:

BCL2 staining is used to distinguish follicular hyperplasia of lymph node (germinal centers are BCL2 negative) from follicular lymphoma (germinal centers are BCL2 positive). However, there are reported cases of follicular lymphomas that are BCL2 negative (Am J Surg Pathol 2011;35:1691, Am J Surg Pathol 2009;33:591). BCL2 staining can also identify immature enteric ganglion cells in pediatric intestinal pseudo-obstruction (Am J Surg Pathol 2005;29:1017). BCL2 antibodies label diffuse large cell lymphoma which is an adverse prognostic factor in some studies (Mod Pathol 2005;18:1113, Clin Cancer Res 2011;15:7785). Myelodysplastic syndrome patients should be screened for BCL2 as increased expression is associated with progression. Finally, BCL2 may have prognostic value in early stage breast cancer (Br J Cancer 2010;103:668).

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “Bcl-2 Oncoprotein [100/D5] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

Bcl-2 Oncoprotein [100/D5] Antibody (cGMP).